• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

干扰素:药代动力学与毒性

Interferon: pharmacokinetics and toxicity.

作者信息

Scott G M

出版信息

Philos Trans R Soc Lond B Biol Sci. 1982 Sep 24;299(1094):91-107. doi: 10.1098/rstb.1982.0109.

DOI:10.1098/rstb.1982.0109
PMID:6183699
Abstract

Interferons disappear rapidly from the serum of animals and man, and the kidney may be the major site of interferon destruction. The relevance of serum levels of interferons to their therapeutic activity has not been clearly established, particularly as the stimulation of host defence mechanisms by interferons may be important. Relatively low serum levels of antiviral activity are seen after intramuscular injections of fibroblast interferon compared with those after the same dose of leucocyte interferon. Injections of very pure leucocyte and lymphoblastoid interferons from several sources cause fever, headaches, malaise and myalgia associated with a corticosteroid response and probably with inflammatory prostaglandin synthesis. These reactions become less with repeated dosing but very large doses of lymphoblastoid interferon have been shown to cause liver damage and serious metabolic disturbances. Treatment with moderate doses of exogenous interferons may occasionally be associated with the development of neutralizing antibodies.

摘要

干扰素在动物和人类血清中迅速消失,肾脏可能是干扰素破坏的主要部位。血清中干扰素水平与其治疗活性之间的相关性尚未明确确立,特别是因为干扰素对宿主防御机制的刺激可能很重要。与相同剂量的白细胞干扰素相比,肌肉注射成纤维细胞干扰素后血清中抗病毒活性水平相对较低。注射来自多个来源的非常纯的白细胞和淋巴母细胞样干扰素会引起发热、头痛、不适和肌痛,这些症状与皮质类固醇反应有关,可能还与炎症性前列腺素合成有关。随着重复给药,这些反应会减轻,但已表明非常大剂量的淋巴母细胞样干扰素会导致肝损伤和严重的代谢紊乱。用中等剂量的外源性干扰素治疗偶尔可能会出现中和抗体。

相似文献

1
Interferon: pharmacokinetics and toxicity.干扰素:药代动力学与毒性
Philos Trans R Soc Lond B Biol Sci. 1982 Sep 24;299(1094):91-107. doi: 10.1098/rstb.1982.0109.
2
Pharmacokinetics and side effects of interferon in man.干扰素在人体中的药代动力学及副作用
Tex Rep Biol Med. 1977;35:541-7.
3
Toxicity of interferon.干扰素的毒性
Br Med J (Clin Res Ed). 1981 Apr 25;282(6273):1345-8. doi: 10.1136/bmj.282.6273.1345.
4
[Interferons--its method of administration and adverse effect related to pharmacokinetics ].[干扰素——其给药方法及与药代动力学相关的不良反应]
Gan To Kagaku Ryoho. 1984 Feb;11(2):186-93.
5
Prevention of vaccinia lesions in Rhesus monkeys by human leucocyte and fibroblast interferon.人白细胞干扰素和成纤维细胞干扰素对恒河猴牛痘损伤的预防作用
J Gen Virol. 1980 May;48(1):25-30. doi: 10.1099/0022-1317-48-1-25.
6
Neutralizing antibodies against human leukocyte, lymphoblastoid and fibroblast interferons elicited by immunization with human leukocyte interferon.用人白细胞干扰素免疫引发的针对人白细胞、淋巴母细胞和成纤维细胞干扰素的中和抗体。
Acta Pathol Microbiol Scand C. 1978 Dec;86C(6):291-8. doi: 10.1111/j.1699-0463.1978.tb02593.x.
7
Evaluation of routes of administration of interferon in cancer: a review and a proposal.
Cancer Drug Deliv. 1984 Fall;1(4):337-51. doi: 10.1089/cdd.1984.1.337.
8
Human lymphoblastoid cells as a source of interferon.人淋巴母细胞作为干扰素的来源。
Dev Biol Stand. 1977;38:343-8.
9
Interferon: mechanisms of action and clinical value.
Clin Pharm. 1983 Jan-Feb;2(1):20-8.
10
The pharmacology and toxicology of the interferons: an overview.干扰素的药理学与毒理学概述
Annu Rev Pharmacol Toxicol. 1986;26:455-515. doi: 10.1146/annurev.pa.26.040186.002323.

引用本文的文献

1
Hepatitis C and kidney disease: A narrative review.丙型肝炎与肾脏疾病:一篇叙述性综述。
J Adv Res. 2017 Mar;8(2):113-130. doi: 10.1016/j.jare.2016.07.004. Epub 2016 Jul 26.
2
Antiviral treatment prioritization in HCV-infected patients with extrahepatic manifestations - An Egyptian perspective.在合并肝外表现的 HCV 感染患者中进行抗病毒治疗的优先排序 - 埃及视角。
J Adv Res. 2016 May;7(3):391-402. doi: 10.1016/j.jare.2016.02.006. Epub 2016 Mar 2.
3
Divergent in vivo and in vitro antileukemic activity of recombinant interferon beta in patients with chronic-phase chronic myelogenous leukemia.
重组干扰素β在慢性期慢性粒细胞白血病患者体内和体外的抗白血病活性存在差异。
Ann Hematol. 1993 Nov;67(5):205-11. doi: 10.1007/BF01715048.
4
[Beta interferon therapy in hairy cell leukemia].
Klin Wochenschr. 1987 Jul 15;65(14):688-90. doi: 10.1007/BF01875507.
5
Tolerance of one-month intranasal interferon.一个月鼻内干扰素耐受性
J Med Virol. 1985 Oct;17(2):99-106. doi: 10.1002/jmv.1890170202.
6
Interferons as cytokines regulating leukocyte functions in vivo.干扰素作为在体内调节白细胞功能的细胞因子。
Ann Inst Pasteur Immunol (1985). 1985 Jul-Aug;136D(1):73-7. doi: 10.1016/s0769-2625(85)80078-7.
7
Safety evaluation of biotechnology products.
Drug Saf. 1990;5 Suppl 1:58-64. doi: 10.2165/00002018-199000051-00009.
8
Pharmacokinetics of recombinant interferon alpha-C.重组干扰素α-C的药代动力学
Cancer Chemother Pharmacol. 1991;27(5):406-8. doi: 10.1007/BF00688867.